1-3 of 3
Vadim V. Romanov
Close
Sort by
Journal Articles

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James E. Signorovitch, Vadim V. Romanov, Frederick L. Locke, David G. Maloney
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1432–1439.
https://doi.org/10.1182/bloodadvances.2019001304
Published: 2020
Includes: Supplemental data
Journal Articles

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Richard T. Maziarz, Stephen J. Schuster, Vadim V. Romanov, Elisha S. Rusch, Junlong Li, James E. Signorovitch, David G. Maloney, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1440–1447.
https://doi.org/10.1182/bloodadvances.2019001305
Published: 2020
Includes: Supplemental data
Journal Articles

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Clinical Trials & Observations
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2230–2236.
https://doi.org/10.1182/bloodadvances.2019000151
Published: 2019